150 Participants Needed

Imaging Device for Needle Biopsy

RA
Overseen ByRahul A Sheth, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

To learn if an investigational imaging device can help to identify tumor tissue before a biopsy is taken.

Will I have to stop taking my current medications?

If you are taking antiplatelet or anticoagulation medications, you may need to stop them 48 hours before the procedure, unless the study doctor decides otherwise. Other medications, including standard chemotherapy, immunotherapy, or targeted therapy, are allowed.

What data supports the effectiveness of the treatment tVisio-1 in the clinical trial Imaging Device for Needle Biopsy?

The research suggests that using a single needle design for image-guided biopsies in various organs is feasible and effective, which may support the use of tVisio-1 if it involves similar technology. Additionally, studies on automated and semi-automated biopsy devices show promising results in terms of diagnostic efficacy and safety, indicating potential effectiveness for tVisio-1.12345

Is the imaging device for needle biopsy generally safe for humans?

The imaging device for needle biopsy, including methods like endoscopic ultrasound-guided biopsy, appears to be generally safe with few incidents reported, such as minor bleeding or hematomas. However, caution is advised for patients with certain conditions like liver cirrhosis or hypervascular tumors, as they may have a higher risk of complications.678910

How does the Imaging Device for Needle Biopsy treatment differ from other treatments?

This treatment uses a unique precision placement technique for biopsy needles, allowing for accurate and less traumatic procedures by using servo-controlled micro-pulses to guide the needle. It also includes an anti-seeding system to prevent the spread of tumor cells during the procedure, which is not commonly found in other biopsy methods.34111213

Research Team

RA

Rahul A Sheth, MD

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults (18+) with a primary or suspected diagnosis of cancer, specifically in the lymph node, liver, or lung. They should have lesions suitable for biopsy and be able to stop blood-thinning medications before the procedure. People can't join if they're pregnant/nursing without contraception, have severe illnesses that could affect participation, or an active infection.

Inclusion Criteria

Platelet count >50,000/mm3 within 6 weeks of screening
Life expectancy ≥ 3 months
Ability to understand and the willingness to sign a written informed consent document
See 7 more

Exclusion Criteria

Absolute neutrophil count <1000 mm3 within 6 weeks of screening
I am not pregnant or nursing, and if capable of becoming pregnant, I am using effective birth control.
I do not have any severe illnesses or conditions that would stop me from following the study's requirements.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Biopsy

Participants undergo OCT imaging to identify tumor tissue before biopsy, followed by the collection of biopsy cores

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure

1 year

Treatment Details

Interventions

  • tVisio-1
Trial Overview The study is testing tVisio-1, an investigational imaging device designed to detect tumor tissue more accurately during needle biopsy procedures on patients with certain types of malignant lesions.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: tVisio-1Experimental Treatment1 Intervention
The device collects optical coherence tomography (OCT) images in an effort to identify tumor tissue before physical samples are collected. During the biopsy, a sterilized optical imaging probe will be placed through the standard biopsy guidance needle to collect a few images of the tissue at the tip of the biopsy needle. Then the regular biopsy will continue to collect a few biopsy cores.

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Findings from Research

In a study of 100 consecutive biopsies using a specialized 18-gauge needle, a specific diagnosis was achieved in 99 out of 100 cases across various organs, demonstrating high efficacy in obtaining tissue samples.
The procedure had a low complication rate, with only 8 minor complications and 3 major complications reported, indicating that this image-guided biopsy technique is safe for use in clinical practice.
Application of a single needle type for all image-guided biopsies: results of 100 consecutive core biopsies in various organs using a novel tri-axial, end-cut needle.Diederich, S., Padge, B., Vossas, U., et al.[2019]
Transjugular liver biopsy using a semi-automatic Tru-cut system was successful in 94% of the 85 patients studied, providing good quality tissue samples for diagnosis in 89% of cases, making it a reliable method for evaluating liver disorders, especially in patients with coagulopathies.
While the procedure is generally safe, there were some complications, including a 1% rate of procedure-related mortality and 8 total complications, indicating that while effective, careful consideration of risks is necessary.
[Transjugular liver core biopsy: indications, results, and complications].Dinkel, HP., Wittchen, K., Hoppe, H., et al.[2019]
In a study involving 29 patients with liver dysfunction, an automated device for transjugular liver biopsy successfully obtained adequate tissue samples in all cases, with an average length of 12.0 mm, allowing for confident histopathologic diagnoses.
The procedure was performed without any complications, highlighting the safety and efficacy of using an automated device for liver biopsies in patients where traditional methods were contraindicated.
Transjugular liver biopsy with an automated device.Kardache, M., Soyer, P., Boudiaf, M., et al.[2004]

References

Application of a single needle type for all image-guided biopsies: results of 100 consecutive core biopsies in various organs using a novel tri-axial, end-cut needle. [2019]
[Transjugular liver core biopsy: indications, results, and complications]. [2019]
Transjugular liver biopsy with an automated device. [2004]
Model-Based Needle Identification Using Image Analysis and Needle Library Matching for Ultrasound-Guided Kidney Biopsy: A Feasibility Study. [2023]
Diagnostic efficacy, performance and safety of side-cut core needle biopsy for thyroid nodules: comparison of automated and semi-automated biopsy needles. [2022]
Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era. [2022]
Incidence and Risk Factors for Adverse Events Related to Image-Guided Liver Biopsy. [2022]
Endoscopic ultrasound-guided transvascular needle biopsy of thoracic and abdominal lesions: a multicenter experience. [2020]
Comparison of Adverse Events of Different Endoscopic Ultrasound-Guided Tissue Acquisition Methods: A Single-Center Retrospective Analysis. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Comparison of a new aspiration needle device and the Quick-Core biopsy needle for transjugular liver biopsy. [2019]
A new method to gently place biopsy needles or treatment electrodes into tissues with high target precision. [2017]
A novel stereotactic frame for real PET-guided biopsies: A preclinical proof-of-concept. [2018]
13.United Statespubmed.ncbi.nlm.nih.gov
A guidance device for CT-guided procedures. [2004]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security